Epworth Sleepiness Scale

Excessive daytime sleepiness (EDS) is the tendency to fall asleep unintentionally or to fall asleep in inappropriate situations during normal waking hours. It is distinct from fatigue (physical or mental tiredness without an increased drive to sleep). EDS affects approximately 10–15% of the adult population and is most commonly caused by obstructive sleep apnoea, insufficient sleep, idiopathic hypersomnia, narcolepsy, medication side effects, or circadian rhythm disorders.

The ESS has been translated and validated in over 50 languages with good reliability coefficients (Cronbach's alpha typically 0.73–0.88). However, cultural differences in sleepiness norms and reporting tendencies may affect population-level scores; normal reference ranges may need adjustment for different cultural contexts. ESS reliability is higher in clinical populations than in community surveys.

The ESS measures subjective sleepiness but cannot identify its cause. It is a screening tool that indicates severity of EDS rather than diagnosis. An ESS >10 should trigger clinical evaluation including sleep history, medication review, questionnaires for OSA (STOP-BANG), and formal sleep studies (polysomnography or home sleep testing) to identify the underlying sleep disorder.

NHS funding criteria for CPAP vary by region, but NICE CG173 (2014) recommends CPAP for adults with moderate-to-severe OSA (AHI ≥15/h) or for mild OSA (AHI 5–14/h) when ESS >9 or there are other relevant comorbidities (cardiovascular risk, occupational sleepiness). An ESS >10 combined with confirmed OSA on sleep study is the typical threshold for treatment initiation.

The Multiple Sleep Latency Test (MSLT) is an objective measurement of daytime sleepiness conducted in a sleep laboratory. The patient undergoes 4–5 nap opportunities across the day; sleep latency is measured for each nap. Mean sleep latency <8 minutes indicates abnormal sleepiness; <5 minutes is severe. The MSLT is the gold-standard objective measure for narcolepsy diagnosis (requires ≥2 SOREMPs) and correlates moderately with the ESS — they measure related but distinct aspects of sleepiness.

ESS scores tend to be slightly lower in older adults compared to young and middle-aged adults — partly because older adults may have adapted their lifestyle to avoid somnolent situations or may have reduced awareness of sleepiness. Reference ranges for the ESS are based predominantly on adult populations aged 20–60; interpretation should be contextualised in elderly patients where lower absolute scores may still represent clinically meaningful sleepiness.

In the context of Epworth Sleepiness, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of business practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.

The ESS was developed for adults. A paediatric version (PDSS — Paediatric Daytime Sleepiness Scale) was developed for children. However, the ESS can be administered to adolescents (≥12 years) with good reliability. For younger children, parent-reported sleepiness measures (CSHQ — Children's Sleep Habits Questionnaire) are preferred. Sleepiness in school-age children is more commonly manifested as hyperactivity and inattention than as overt dozing.